Celldex Therapeutics, Inc. (CLDX) Q4 2018 Earnings Results

Celldex Therapeutics Misses on Revenue, Stock Down 1.71%

Celldex Therapeutics reported a larger-than-expected loss per share, which was a positive surprise despite the lack of revenue figures. The stock reacted negatively, declining by 1.71%. Investors may be concerned about the absence of revenue data and future guidance, which could indicate uncertainty in the company's financial outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.81	N/A	+24.58%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management emphasized the importance of their clinical pipeline. However, they did not provide specific guidance or expectations for future revenue.

Management did not provide specific revenue figures or future guidance.

The focus remains on ongoing clinical trials and product development.

Celldex Therapeutics Misses on Revenue, Stock Down 1.71%

Key numbers

Management commentary

Celldex Therapeutics, Inc.

More earnings this week

Celldex Therapeutics Misses on Revenue, Stock Down 1.71%

Key numbers

Management commentary